Azure Biology: Enzyme preparation faucet + new sugar substitute

(Reasons for concern: short-term, market funds return to consumption〉

1. Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, has made significant progress in the synthesis of starch. The researchers of the institute proposed a subversive starch preparation method, without relying on plant photosynthesis, using carbon dioxide and hydrogen produced by electrolysis as raw materials, and finally successfully produced starch through biological channels, which realized the de novo synthesis of carbon dioxide to starch for the first time in the world, making it possible to transform starch production from traditional agricultural planting mode to industrial workshop production mode.

The company has many years of scientific research accumulation in food enzyme catalysis technology and plant-based fermentation technology, breaking the international monopoly in the field of segmentation. The company's core technical personnel are born in the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, and have long-term technical cooperation with Tianjin Industrial Biology.

2. Increase liver glycogen content, reduce body fat accumulation, and avoid the occurrence of postprandial hyperglycemia in diabetics; in experiments, it can also inhibit the activity of liver lithase in mice, reduce the accumulation of abdominal fat, and can assist in weight loss. The company's enzyme preparations can be used to process and produce allulose.

3. The company's 21H1 revenue was +27.3% year-on-year to 550 million yuan, and the net profit attributable to the mother was +39.5% to 0.6 billion yuan year-on-year. 21H1 gross margin -6.1% to 46.4% yoY, net margin +6.3% to 11.75% yoY, and three expense ratios -6.6% to 34.05% o

By product, the company's 21H1 performance of feed and livestock and poultry products has grown rapidly. On the one hand, the company benefited from the rapid growth of feed prohibition for the demand for anti-resistance products. And with the increase in the application ratio of unconventional raw materials at the word end, the company's feed enzyme products can effectively improve the efficiency of feed conversion, help the breeding end reduce costs, and the recognition of downstream large customers continues to increase. On the other hand, the advantages of the company's products + services are obvious, which strongly supports the terminal premium, the company not only for the feed ban anti-resistance forward-looking layout of a number of systematic product portfolio programs, in the word end of the formation of enzymes, probiotics, plant extracts of the "anti-iron triangle", but also provide feed end quality control v in vitro and in vitro gastrointestinal model and other comprehensive services, enhance customer stickiness. At the same time, enzyme preparations can significantly reduce energy consumption, in line with the trend of carbon emission reduction, 2021H1 company sales of enzyme products in downstream customer applications, a cumulative reduction of carbon dioxide emissions of about 970,000 tons.

4. The company released the first equity incentive plan in June 21, the number of stock options to be granted to the incentive object is 10 million, the exercise price is 13.44 yuan / share, the total number of incentive objects granted is 50 people, and the unlocking conditions for the five exercise periods are respectively, the net profit attributable to the shareholders of the listed company from 2021 to 2025 increased by 25.40%, 32.00%, 55.00%, 75.00%, 132.00% compared with 2020, respectively, This is equivalent to a performance target of 18.06% of the net profit attributable to the mother CAGR in the next 5 years.

5. The company is mainly engaged in the research and development, production and sales of enzyme preparations, microecology and animal health products. The main products are enzyme preparations, micro-ecological products, animal protection series products; subsidiary Azure Biological Products has signed a "Cooperative Research Agreement" with harbin veterinary drug research institute of Chinese Academy of Agricultural Sciences Co., Ltd., and participated in the research of African swine fever and other livestock vaccines carried out by Harbin Veterinary Medicine Research Institute Of Chinese Academy of Agricultural Sciences Co., Ltd.